Skip to search formSkip to main contentSkip to account menu

rasagiline

Known as: (R)-Indan-1-yl-prop-2-ynyl-amine, rasagiline [Chemical/Ingredient], RAS 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Objective: The objective of this review was to update evidence‐based medicine recommendations for treating motor symptoms of… 
Highly Cited
2009
Highly Cited
2009
BACKGROUND A therapy that slows disease progression is the major unmet need in Parkinson's disease. METHODS In this double… 
Highly Cited
2009
Highly Cited
2009
To identify susceptibility variants for Parkinson's disease (PD), we performed a genome-wide association study (GWAS) and two… 
Review
2006
Review
2006
Objective:To make evidence-based treatment recommendations for the medical and surgical treatment of patients with Parkinson… 
Highly Cited
2005
Highly Cited
2005
  • Archives of neurology
  • 2005
  • Corpus ID: 22841106
BACKGROUND Rasagiline (n-propargyl-1[R]-aminoindan) mesylate is a novel irreversible selective monoamine oxidase type B inhibitor… 
Review
2005
Review
2005
Rasagiline is a novel second‐generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO‐B… 
Highly Cited
2002
Highly Cited
2002
The role of mitochondrial permeability transition (PT) in apoptosis induced by an endogenous neurotoxin, N‐methyl(R)salsolinol… 
Highly Cited
2001
Highly Cited
2001
Rasagiline [N‐propargyl‐1R(+)‐aminoindan], was examined for its monoamine oxidase (MAO) A and B inhibitor activities in rats…